LON:RENX Renalytix (RENX) Share Price, News & Analysis GBX 3.74 0.00 (0.00%) As of 04:18 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider Trades About Renalytix Stock (LON:RENX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Renalytix alerts:Sign Up Key Stats Today's Range 3.70▼ 3.7450-Day Range 1.86▼ 4.5052-Week Range 1.60▼ 15.50Volume88 shsAverage Volume911,358 shsMarket Capitalization£16.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com. Read More Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENX Stock News HeadlinesRenalytix PLCJuly 7, 2026 | marketwatch.comRenalytix shares climb 24% as two-year kidney study data publishedJune 30, 2026 | finance.yahoo.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool ExistsJune 30, 2026 | finance.yahoo.comRenalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision InterventionMay 12, 2026 | tmcnet.comRenalytix shares fall 25% as revenues miss expectationsFebruary 11, 2026 | finance.yahoo.comRenalytix expands kidney disease test adoption and strategic partnershipsDecember 9, 2025 | msn.comRenalytix’s KidneyIntelX.dkd Test Gains Recognition for Advancing CKD ManagementNovember 12, 2025 | msn.comSee More Headlines RENX Stock Analysis - Frequently Asked Questions How have RENX shares performed this year? Renalytix's stock was trading at GBX 5.80 at the start of the year. Since then, RENX stock has decreased by 35.6% and is now trading at GBX 3.74. How were Renalytix's earnings last quarter? Renalytix Plc (LON:RENX) released its quarterly earnings results on Tuesday, October, 1st. The company reported ($31.00) EPS for the quarter. Renalytix had a positive trailing twelve-month return on equity of 675.00% and a negative net margin of 506.25%. How do I buy shares of Renalytix? Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD). Company Calendar Last Earnings10/01/2024Today8/23/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolLON:RENX CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (4) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£109.93 million Net Margins-506.25% Pretax MarginN/A Return on Equity675.00% Return on Assets-93.54% Debt Debt-to-Equity Ratio-483.33 Current Ratio1.57 Quick Ratio2.42 Sales & Book Value Annual Sales£3.30 million Price / Sales4.90 Cash FlowGBX 2.02 per share Price / Cash Flow1.84 Book ValueGBX (10.71) per share Price / Book-0.35Miscellaneous Outstanding Shares437,019,000Free FloatN/AMarket Cap£16.17 million OptionableNot Optionable Beta1.81 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:RENX) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe Musk-linked sector everyone's sleeping onMicron, a key Musk supplier, surged 1,121% in under two years after Jeff Brown flagged it early. Now Brown ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
